Journal
Cancer Chemotherapy and Pharmacology
Publication Date
2017
Volume
79
Issue
2
Inclusive Pages
339-351
Document Type
Open Access Publication
DOI
10.1007/s00280-016-3210-8
Rights and Permissions
Sarantopoulos, J., Mita, A.C., He, A. et al. Cancer Chemother Pharmacol (2017) 79: 339. doi:10.1007/s00280-016-3210-8 © The Author(s) 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Recommended Citation
Sarantopoulos, John; Mita, Alain C.; He, Aiwu; Wade, James L.; Hsueh, Chung-Tsen; Morris, John C.; Lockhart, A. Craig; Quinn, David I.; Hwang, Jimmy; Mier, James; Zhang, Wenping; Wack, Claudine; Yin, Jian; Clot, Pierre-Francois; and Rixe, Olivier, "Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: A phase I dose-escalation study." Cancer Chemotherapy and Pharmacology. 79, 2. 339-351. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5898
